Frequently Asked Questions
PRAXBIND is a humanized monoclonal antibody fragment (Fab) indicated in patients treated with PRADAXA when reversal of the anticoagulant effects of dabigatran is needed:
- For emergency surgery/urgent procedures
- In life-threatening or uncontrolled bleeding
This indication is approved under accelerated approval based on a reduction in unbound dabigatran and normalization of coagulation parameters in healthy volunteers. Continued approval for this indication may be contingent upon the results of an ongoing cohort case series study.
For intravenous use only. The recommended dose of PRAXBIND is 5 g, provided as two separate vials, each containing 2.5 g/50 mL of PRAXBIND.
One recommended dose for all PRADAXA patients.
For intravenous use only.
Ready to use immediately
- The recommended dose of PRAXBIND is 5 g, provided as two separate 50 mL vials, each containing 2.5 g
- There are limited data to support administration of an additional 5 g of PRAXBIND
- No reconstitution needed
- Ensure aseptic handling when preparing and administering the infusion
- Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit
- Once solution has been removed from the vial, administration should begin promptly or within 1 hour
Flexible administration for immediate reversal:
Option 1: Infusion
- Hang vials and administer as 2 consecutive infusions
Option 2: Bolus Injection
- Inject both vials consecutively via syringe
PRAXBIND is a humanized monoclonal antibody fragment (Fab) that specifically binds to dabigatran and its acylglucuronide metabolites and reverses their anticoagulant effect immediately after administration.
In healthy volunteers, the most frequently reported adverse reaction in ≥5% of PRAXBIND‑treated subjects was headache. In patients, the most frequently reported adverse reactions in ≥5% of patients were hypokalemia, delirium, constipation, pyrexia and pneumonia.
Inform patients that reversing dabigatran therapy exposes them to the thromboembolic risk of their underlying disease. To reduce this risk, resumption of anticoagulant therapy should be considered as soon as the patient is sufficiently stable.
Recurrence of Bleeding
Inform patients to get immediate medical attention for any signs or symptoms of bleeding.
Inform patients of signs and symptoms of allergic hypersensitivity reactions such as anaphylactoid reactions that may be experienced during or after injection of PRAXBIND.
Risk of Serious Adverse Reactions in Patients with Hereditary Fructose Intolerance due to Sorbitol Excipient
Inform patients with hereditary fructose intolerance (HFI) that PRAXBIND contains sorbitol. Parenteral administration of sorbitol in patients who have HFI has been associated with reports of hypoglycemia, hypophosphatemia, metabolic acidosis, increase in uric acid, acute liver failure with breakdown of excretory and synthetic function, and death and may occur during or after injection of PRAXBIND.
- Renal clearance: 47.0 mL/minute (gCV 18.4%)
- Initial half-life: 47 minutes (gCV 11.4%)
- Terminal half-life: 10.3 hours (gCV 18.9%)
- <1% recovered in urine after 24 hours; 32.1% after 6 hours
- Remainder of dose assumed to be eliminated via protein catabolism
- Age, sex, race (Caucasian vs Asian) and body weight had no clinically important effect on exposure†
- In vitro data suggest that reversal of PRADAXA is not affected by:
- Coagulation factor concentrates‡
- In animal studies, it was suggested that neutralization of anticoagulant activity is not influenced by 50% hemodilution with routinely used volume replacement strategies§
For complete information on the pharmacokinetics of PRAXBIND, please see the Prescribing Information.
Renal impairment did not impact the reversal effect of idarucizumab. No dose adjustment is required in renally‑impaired patients.
- In a study of subjects with renal impairment (mild, n=12; moderate, n=6)*, the total clearance was reduced vs healthy subjects
- This led to an increase in PRAXBIND’s area under the curve (mild 43.5%; moderate 83.5%)
- Store PRAXBIND vials in the refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Do not shake
- Prior to use, the unopened vial may be kept at room temperature 25°C (77°F) for up to 48 hours, if it’s kept in its original packaging. This packaging protects it from light. When exposed to light, it may be kept for 6 hours
Search our database to locate a facility in your area that has PRAXBIND available:
PRAXBIND was awarded NTAP status, effective October 1st, 2016. Click here to learn more.
Please click here for the latest information on how to order PRAXBIND.
You can contact our Medical Information Service 24 hours a day, 7 days a week by calling 1‑800‑542‑6257 (Opt 1).
The Boehringer Ingelheim Pharamaceuticals, Inc. Return Goods Policy for PRAXBIND applies to products purchased from an Authorized Distributor of Record (ADR) that is duly licensed as a provider to dispense BIPI product. Please contact BI Customer Service at (800) 243‑0127 for additional details.